Clinuvel Pharmaceuticals (ASX:CUV) — Material Events
ASX:CUV · 13 articles in the last 12 months · 100% assessed
Click a band to jump to that tier
Major ≥90
Significant 75–89
Notable 50–74
Routine <50
Not assessed
CLINUVEL Stays the Course: CEO Retained as Vitiligo Program Takes Centre StageMedium
CLINUVEL Retains CEO Wolgen, Prioritizes Vitiligo Program, Eyes Nasdaq Listing in 2026
20 Mar 2026
·CEO Letter / Strategic Update
·85
CLINUVEL Shifts Headquarters to US and Cuts Workforce to Target US MarketMedium
CLINUVEL to relocate headquarters to U.S. and refocus operations on U.S. market with workforce reduction
23 July 2026
·Strategic Reorganisation
·85
Health Canada Grants Approval for CLINUVEL’s SCENESSE to Treat Rare EPP DisorderMedium
Health Canada approves SCENESSE® for EPP treatment, expanding CLINUVEL's market
13 July 2026
·Regulatory Approval
·85
CLINUVEL Secures EMA Nod for Pivotal Vitiligo Phase III Trial of SCENESSEMedium
CLINUVEL secures EMA scientific advice for pivotal Phase III vitiligo study with SCENESSE®
24 Apr 2026
·Regulatory Update
·85
Clinuvel Reports Tenth Profit, Plans Nasdaq Listing and U.S. HQ MoveMedium
Clinuvel reports FY2026 results with slight revenue decline, expands U.S. presence, and plans Nasdaq full listing
27 Aug 2026
·Annual Report
·85
EMA Greenlights Year-Round SCENESSE® for EPP, Lifting Dose CapsMedium
EMA approves year-round SCENESSE® treatment for EPP, removing dose limits
23 Sept 2025
·Regulatory Approval
·85
CLINUVEL Boosts Singapore Hub to Lead Next-Gen Peptide TherapiesMedium
CLINUVEL expands Singapore RD&I Centre to pioneer next-gen peptide therapies with five-year strategic investment
8 Dec 2025
·ASX Announcement
·75
Clinuvel Sets December 2026 for Vitiligo Trial Results, Phase III to Start NovemberMedium
Clinuvel updates vitiligo SCENESSE® trials with topline results expected December 2026 and Phase III start in November
28 July 2026
·Clinical Trial Update
·75
FDA Drops Cardiac QT Study for SCENESSE, Citing Strong Safety DataMedium
FDA drops cardiac QT study requirement for SCENESSE®, confirming strong safety profile
27 Apr 2026
·Regulatory Update
·Unexpected
·75
Health Canada Extends SCENESSE® Review, Delaying EPP Treatment ApprovalMedium
Health Canada delays SCENESSE® approval for EPP, review extended to 2026
16 Oct 2025
·ASX Announcement
·Unexpected
·70
Clinuvel Advances Peptide Drug Delivery with VLRX-L Preclinical DosingMedium
Clinuvel starts preclinical dosing of novel controlled-release peptide platform VLRX-L, results due H2 2026
12 Jan 2026
·ASX Announcement
·70
CLINUVEL Unveils Promising Vitiligo Repigmentation Cases with SCENESSE®Medium
CLINUVEL presents positive vitiligo repigmentation case studies for SCENESSE® at EADV
19 Sept 2025
·ASX Announcement
·70
No articles in this tier for the last 12 months.
Market Mentions
11
- appeared in market wrap coverage
These are market wrap articles where Clinuvel Pharmaceuticals (ASX:CUV) was mentioned. They reflect broader market coverage, not company-specific announcements.
Healthcare Wrap - Week 35 (24 Aug -> 28 Aug) 2026
29 Aug 2026
Healthcare Wrap - Week 31 (27 July -> 31 July) 2026
1 Aug 2026
Market Wrap - Week 30 (20 July -> 24 July) 2026
25 July 2026
Healthcare Wrap - Week 30 (20 July -> 24 July) 2026
25 July 2026
Market Wrap - Week 29 (13 July -> 17 July) 2026
18 July 2026
Healthcare Wrap - Week 29 (13 July -> 17 July) 2026
18 July 2026
Healthcare Wrap - Week 25 (15 June -> 19 June) 2026
20 June 2026
Healthcare Wrap - Week 18 (27 Apr -> 1 May) 2026
2 May 2026
Healthcare Wrap - Week 17 (20 Apr -> 24 Apr) 2026
25 Apr 2026
Market Wrap - Week 12 (16 Mar -> 20 Mar) 2026
21 Mar 2026
Healthcare Wrap - Week 12 (16 Mar -> 20 Mar) 2026
21 Mar 2026